Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Индивидуальное лечение табакокурения в первичной медико-санитарной помощи

2 ноября 2026 г. обновлено: Washington University School of Medicine

Многоуровневое вмешательство для персонализации и улучшения лечения табакокурения в первичной медико-санитарной помощи

This study examines the application of precision treatment intervention for smoking cessation from both the clinician perspective and patient perspective, and compares it to usual care on tobacco treatment in the primary care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This approach may increase effectiveness and adherence for the patient, and increase the clinician's likelihood of prescribing.

Обзор исследования

Подробное описание

The overarching goal of this study is to test the impact of a multilevel precision treatment intervention aiming to address gaps in clinician and patient uptake of tobacco treatment and overall treatment effectiveness. This study builds on evidence that (1) genetic and metabolic factors may inform precision tobacco treatment and (2) increasingly high demand for precision treatment, in particular, may signal its potential to activate behavior change. The multilevel precision treatment intervention to be tested--PrecisionTx-- provides the opportunity to present personalized risk, benefit, and treatment recommendation to increase clinician ordering, patient uptake, and overall effectiveness of tobacco treatment. This study aims to understand the relative benefit of precision treatment over usual care and associated mechanistic and implementation outcomes. Therefore, the investigators propose a 2-arm cluster randomized controlled trial of 50 clinicians and 800 screen-eligible patients (~16 per clinician) from diverse primary care settings. Clinicians and patients will be randomized with 1:1 allocation to usual care (UC) vs. precision treatment (PT) to evaluate the effect of precision treatment on smoking cessation success. In Aim 1, the investigators will test the effect of PT on clinician prescribing (or patient receipt of medication when prescription is not needed) and patient use of medication for smoking cessation. The investigators hypothesize that patient receipt of tobacco treatment medication for smoking cessation at 6 months post-intervention will be higher in PT vs UC. The investigators also hypothesize that patient use of cessation medication at 6 months post-intervention will be higher in PT vs. UC. In Aim 2, the investigators will test the effect of PT on patient smoking abstinence. The investigators hypothesize that patient bioverified smoking abstinence at 6 months will be higher in PT vs. UC. In Aim 3, the investigators will examine mechanisms of behavior change and implementation outcomes. The investigators will evaluate putative mechanisms for PT (e.g., outcome expectancy and withdrawal suppression). The investigators will conduct assessments at baseline, intervention, and 1-month, 3-month, 6-month, and 12-month post-intervention follow-ups.

Primary outcomes include patient receipt of tobacco treatment, patient use of tobacco treatment, and patient smoking abstinence. Secondary outcomes include patient receipt of recommended medication, patient medication adherence, and additional patient smoking cessation outcomes. Mechanistic outcomes include clinician level (perceived benefit, outcome expectancy), clinician-patient interaction (self-efficacy), patient-level (perceived risk, outcome expectancy, withdrawal suppression, adverse events). Implementation outcomes will be evaluated based on the RE-AIM framework. The study is an innovative paradigm shift from a traditional treatment model to precision treatment that includes both metabolic and genetic markers to motivate and guide tobacco treatment for both clinicians and patients, integrated within primary care.

Smoking is a leading cause of premature death, causing more than half of all cancer deaths. However, tobacco treatment is often not provided and is not highly effective in primary care. New evidence suggests that a precision treatment approach to motivate and guide treatment based on personal genetic and metabolic markers could improve treatment uptake and quit success. This study will test the impact of a multilevel precision treatment intervention on improving tobacco treatment and health outcomes in primary care.

Тип исследования

Интервенционный

Регистрация (Оцененный)

850

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Li-Shiun Chen, ScD, MD, MPH
  • Номер телефона: 314-362-3932
  • Электронная почта: li-shiun@wustl.edu

Учебное резервное копирование контактов

  • Имя: Alex Ramsey, PhD
  • Номер телефона: 314-362-5370
  • Электронная почта: aramsey@wustl.edu

Места учебы

    • Missouri
      • St Louis, Missouri, Соединенные Штаты, 63110
        • Рекрутинг
        • Washington University School of Medicine
        • Контакт:
          • Li-Shiun Chen, ScD, MD, MPH
          • Номер телефона: 314-362-3932
          • Электронная почта: li-shiun@wustl.edu
        • Контакт:
          • Alex Ramsey, PhD
          • Номер телефона: 314-362-5370
          • Электронная почта: aramsey@wustl.edu
        • Главный следователь:
          • Li-Shiun Chen, ScD, MD, MPH
        • Главный следователь:
          • Alex Ramsey, PhD
        • Младший исследователь:
          • Laura Bierut, MD
        • Младший исследователь:
          • Esther Lu, PhD
        • Младший исследователь:
          • Robert Schnoll, PhD
        • Младший исследователь:
          • Timothy Baker, PhD
        • Младший исследователь:
          • Hilary Tindle, MD
        • Младший исследователь:
          • Rachel Tyndale, PhD

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Eligibility Criteria for Primary and Specialty Care Clinicians

  • Clinician from participating clinic
  • At least 18 years of age
  • Can speak and understand English

Eligibility Criteria for Primary Care and Specialty Patients

Inclusion:

  • Patient at participating clinic
  • Age 18 years or older, inclusive
  • Current smoking (cigarettes per day >=5)
  • Can speak and understand English
  • Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline

Exclusion:

  • Active use of smoking cessation medication (within the past 30 days)
  • Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)
  • Having a contraindication for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Одинокий

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Активный компаратор: Usual Care

The arm will represent usual care in the primary care clinics. Physicians will receive a report designed to recommend guideline-based tobacco treatment. Patients will receive a report on guideline-based advice about smoking cessation and a brief discussion with a behavior interventionist.

Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).

Экспериментальный: PrecisionTx

Physicians will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment. Patients will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment, and a brief discussion with a behavior interventionist.

Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Patient receipt of tobacco treatment medication for smoking cessation
Временное ограничение: 6 months post-intervention

This will be quantified by the proportion of enrolled patients who receive cessation medication.

6 months post-intervention
Patient use of cessation medication
Временное ограничение: 6 months post-intervention

This will be quantified by the proportion of patients taking any cessation medication from time of enrollment through 6 months post-intervention.

6 months post-intervention
Patient smoking abstinence
Временное ограничение: 6 months post-intervention

This will be quantified by the proportion of smokers with bioverified point-prevalent abstinence at 6 months.

6 months post-intervention

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Patient receipt of recommended tobacco treatment
Временное ограничение: 6 months post-intervention

This will be quantified by the proportion of enrolled patients who received recommended cessation medication.

6 months post-intervention
Patient medication adherence
Временное ограничение: 6 months post-intervention

This will be quantified by the proportion of medication taken among medication prescribed.

6 months post-intervention
Patient smoking abstinence among treated
Временное ограничение: 6 months post-intervention

This will be quantified by the proportion of smokers with bioverified point-prevalence abstinence among those receiving cessation medication.

6 months post-intervention
Abstinence Outcomes Across Multiple Time Points
Временное ограничение: From intervention through 12 months post-intervention

The outcome measures abstinence (self-reported no smoking (not even a puff of a cigarette) for at least 7 days prior to the assessment) over these time points.

From intervention through 12 months post-intervention
Smoking quantity across multiple time points
Временное ограничение: From intervention through 12 months post-intervention

The outcome measures smoking quantity (self-reported average cigarettes smoked per day for the past 30 days prior to the assessment) over these time points.

From intervention through 12 months post-intervention
Quit attempts
Временное ограничение: 6 and 12 months post-intervention

This outcome measures the number of quit attempts in the past 30 days prior to the assessment over these time points.

6 and 12 months post-intervention

Другие показатели результатов

Мера результата
Мера Описание
Временное ограничение
Perceived benefits (Clinician)
Временное ограничение: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' perceived importance and benefits of patients receiving smoking cessation medications will be assessed using a modified version of the Beliefs and Attitudes About Bupropion Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Outcome expectancies (Clinician)
Временное ограничение: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' outcome expectancies regarding tobacco treatment will be assessed using a modified version of the Stanford Expectation of Treatment Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Self-efficacy regarding patient-clinician interaction (Clinician)
Временное ограничение: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' perceived self-efficacy regarding patient-clinician communication will be assessed using a modified version of the Communication Perceived Self-Efficacy Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Self-efficacy regarding patient-clinician interaction (Patient)
Временное ограничение: From intervention through 12 months post-intervention

Patients' perceived self-efficacy regarding patient-clinician communication will be assessed using a modified version of the Communication Perceived Self-Efficacy Scale.

From intervention through 12 months post-intervention
Perceived risk (Patient)
Временное ограничение: From baseline through 12 months post-intervention

Patients' perceived smoking-related disease risks will be assessed using a modified version of the Perceived Susceptibility and Severity Scale.

From baseline through 12 months post-intervention
Outcome expectancies (Patient)
Временное ограничение: From baseline through 12 months post-intervention

Patients' outcome expectancies regarding tobacco treatment will be assessed using a modified version of the Stanford Expectation of Treatment Scale.

From baseline through 12 months post-intervention
Withdrawal
Временное ограничение: From baseline through 12 months post-intervention

Withdrawal severity is assessed by Wisconsin Smoking Withdrawal Scale (WSWS).

From baseline through 12 months post-intervention
Side Effects
Временное ограничение: From baseline through 12 months post-intervention

All reported side effects will be summarized and presented for the study. In addition, the investigators will further identify a pre-specified set of key side effects as being related to drug agonist effects (e.g., nausea, vomiting, racing heart, headache, and sleep disturbance). These will be analyzed as the rate of occurrence during the period of cessation medication use, if applicable.

From baseline through 12 months post-intervention

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Следователи

  • Главный следователь: Li-Shiun Chen, ScD, MD, MPH, Washington University School of Medicine

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

29 сентября 2023 г.

Первичное завершение (Оцененный)

31 марта 2028 г.

Завершение исследования (Оцененный)

30 сентября 2028 г.

Даты регистрации исследования

Первый отправленный

21 апреля 2023 г.

Впервые представлено, что соответствует критериям контроля качества

4 мая 2023 г.

Первый опубликованный (Действительный)

6 мая 2023 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

3 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

2 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • 202205090
  • 1R01DA056050 (Грант/контракт NIH США)
  • 5U19CA203654 (Грант/контракт NIH США)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

The University will share anonymized human genomic data and relevant associated data from approximately 800 research participants by depositing these data in a NIH-designated data repository or other repositories that meet the appropriate data security measures, confidentiality, privacy, and data use measures. The genotype data will be made available 12 months after trial completion in a NIH-designated data repository after data cleaning and quality control completion, which we anticipate to be in year 5, without restrictions on publication or other dissemination. In addition, information necessary to interpret the submitted data will be included, such as study protocols, data instruments and survey tools.

Сроки обмена IPD

12 months after trial completion

Совместное использование IPD Поддерживающий тип информации

  • STUDY_PROTOCOL
  • САП

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться